Freestone Grove Partners’s Biohaven BHVN Stock Holding History

Freestone Grove Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,647	Closed	-$290K	–	993
2025 Q4	$290K	Buy	+25,647	New	+$318K	﹤0.01%	661

Other funds holding BHVN

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's BHVN Position: Q1 2026 in Review

Freestone Grove Partners sold out of Biohaven (BHVN) in Q1 2026, closing a stake of 25,647 shares — an estimated $290K sold.

Freestone Grove Partners first reported a position in BHVN in Q4 2025 and held it in 1 quarter. The position peaked at $290K in Q4 2025. 277 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

Freestone Grove Partners reported no remaining Biohaven position as of Q1 2026 after selling out during the quarter.
Freestone Grove Partners sold 25,647 Biohaven shares in Q1 2026, an estimated $290K.
Freestone Grove Partners first reported a position in Biohaven in Q4 2025 and held it in 1 quarter.
Freestone Grove Partners's Biohaven position peaked at $290K in Q4 2025.
277 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.